This study is testing a type of radiation therapy called adaptive stereotactic body radiation therapy (SBRT) with a SIB for men with intermediate- or high-risk prostate cancer. Researchers want to find the highest dose of this treatment that is safe and doesn't cause serious side effects. They also want to see if this treatment can target the prostate more precisely, reduce radiation exposure to nearby organs, and improve quality of life by reducing urination-related side effects. You may be able to join if you are a man over 18 with histologically confirmed prostate adenocarcinoma and a good general health status. The study aims to enroll 80 participants. The main measure of success for this study is to see if severe side effects (CTCAE grade ≥ 3) occur within 90 days of treatment. The current recruitment status is unclear.

Study design

This is an interventional study with a planned enrollment of 80 participants. It is a phase 1 dose-finding study, meaning it aims to determine the best dose of the treatment.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be monitored for severe side effects for approximately 100 days after treatment. The study also aims to assess side effects over five years post-treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.